AXXE NEWS:Axxess Pharma Inc. Anticipates Additional $700,000 in Annual Sales From Pre-Natal, Non-Constipating Multi-Vitamin Triferrex PN MARKHAM, ON, Aug 26, 2010 (MARKETWIRE via COMTEX) -- Axxess Pharma Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce they anticipate generating an additional $700,000 in annual sales from their pre-natal, non-constipating multi-vitamin Triferrex PN. Pre-natal multi-vitamins are a critical source of nutrients for pregnant women.
Healthcare providers usually advise women to take prenatal multi-vitamin supplements prior to, during, and after pregnancy (postpartum). However, upon taking that advice, many pregnant women struggle with taking the supplement and battle adverse effects such as constipation or other discomforts. When constipation sets in, pregnant women find it tough to continue taking the multi-vitamin thus putting their health and the babies' health in jeopardy. Triferrex PN helps eliminate these problems by providing the careful balance of required nutrients while preventing constipation.
"We look forward to releasing a high demand, pre-natal multi-vitamin Triferrex PN. This product will be launched shortly and is anticipated to generate an additional $700,000 in annual sales. Our current Triferrex multi-vitamin for both men and women has already generated $1.3 million in revenues for 2009. With the rollout of Triferrex PN, we feel confident in surpassing $2.3 million in annual revenue from our Triferrex line," stated Gerald Sequeira, President/CEO.
For more information, please contact Investor Relations at (973) 351-3868.
About Axxess Pharma Inc.:
Axxess Pharma Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.
Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.
The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.